| Description | Tasimelteon (BMS-214778) is a melatonin receptor agonist that is used for the treatment of non-24 hour sleep-wake disorder in blind individuals. |
| Target activity | MT2 receptor:9.8(pKi), MT1 receptor:9.45(pKi) |
| Synonyms | 他司美琼, VEC-162, BMS-214778 |
| molecular weight | 245.32 |
| Molecular formula | C15H19NO2 |
| CAS | 609799-22-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 50 mg/mL (203.82 mM) |
| References | 1. Leger D, et al. Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies. Expert Opin Drug Saf. 2015;14(11):1673-85. 2. Keating GM, et al. Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals. CNS Drugs. 2016 Mar 22. |